Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

26-30 of 56 results for all trials

Sort by:

Filter by

Therapeutic category

Trial status

GLPG2737-CL-105 Assessment of multiple oral doses of GLPG2451/GLPG2222

Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by mutations in the gene encoding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a cAMP-regulated anion channel expressed primarily at the apical plasma membrane of secretory epithelia. Over 2,000 mutations in the CFTR gene have been identified, which are grouped into 6 classes (class I-VI). The F508del mutation is by far the most common CFTR mutation globally, especially in the Caucasian population. Approximately 80 to 90% of CF patients in the United States and Europe have at least one copy of this mutation on one allele, with almost half of them being F508del homozygous (i.e., the mutation is present on both alleles). The F508del mutation impairs CFTR folding, stability at the endoplasmic reticulum and plasma membrane, and chloride gating. Thus, the F508del mutation results in very little to no CFTR protein in the apical membrane. CFTR dysfunction results in increased chloride concentration in sweat and viscous secretions that are difficult to clear, affecting most exocrine glands, notably the pancreas, intestine, liver, and bile duct. However, most morbidity and mortality results from dehydration of the airway surface liquid and impaired airway mucociliary clearance, which leads to cycles of bacterial infection, chronic inflammation, bronchiectasis and progressive decline in pulmonary function. There is a high unmet medical need for subjects with CF, especially for subjects that are either homozygous or heterozygous for the F508del mutation (with a potentiator non-responsive mutation on the second allele). GLPG2451, GLPG2222 and GLPG2737 are in clinical development for the oral treatment of CF, and represent the components of a potentiator/correctors triple combination therapy targeting the F508del CF subject population.

Read more Phase I
  • Trial Reference Number

    104923

  • Age

    18+

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function

Lenabasum in Cystic Fibrosis

This study is designed to evaluate the effectiveness and safety of lenabasum (JBT-101) in people with CF who have had pulmonary exacerbations. Lenabasum (JBT-101) is an oral medication that is aimed at reducing inflammation. It is thought to help the body increase production of anti-inflammatory molecules while reducing production of molecules that increase inflammation. Reduction of inflammation helps prevent permanent tissue damage in the lungs that happens when CF patients have pulmonary exacerbations. For study participants this study includes 6 months of study treatment with a 1 month follow up period. Study participants may remain on their current CF treatments

Read more Phase II
  • Trial Reference Number

    106210

  • Trial status

    Open to recruitment

  • Therapeutic category

    Anti-Inflammatory

Glycaemic Index Dietary Education for glucose abnormalities in Cystic Fibrosis

Few people with Cystic Fibrosis have normal blood glucose control and these glucose abnormalities eventually progress to cystic fibrosis-related diabetes (CFRD), the most common complication of Cystic Fibrosis. People with Cystic Fibrosis are encouraged to consume a high calorie diet to maintain weight. This typically means eating food and drinks that are often high in fat and/or sugar. For people with Cystic Fibrosis who also need to control their blood glucose levels, high sugar intake can make this difficult. There is limited evidence to guide dietary therapy for blood glucose abnormalities in Cystic Fibrosis. Manipulating the glycaemic index (GI) and glycaemic load (GL) of what is consumed may be a possible area for intervention to improve blood glucose control without compromising energy intake. This study will explore the feasibility of delivering glycaemic index/glycaemic load dietary education (GLIDE) in a sample of 20 young people with CF and abnormal blood glucose control. GLIDE intervention will be implemented by participants for 12 weeks. Dietary intake and glycaemic control will be measured at baseline and at 12 week follow-up using an on-line dietary recording tool and continuous glucose monitoring, respectively. The primary objective of this study is to investigate the feasibility of GLIDE intervention in young people with CF and abnormal blood glucose control. Secondary objectives include measuring glycaemic control, energy and nutrient intake, body weight and lung function before GLIDE intervention and at 12-week follow-up.

Read more Not Applicable
  • Trial Reference Number

    107989

  • Length of participation

    4 months

  • Trial status

    Open to recruitment

  • Therapeutic category

    Nutritional-GI

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (VX17-659-102)

A Phase 3, Randomised, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Phase III
  • Trial Reference Number

    105982

  • Mutation

    One copy of F508del

  • Length of participation

    24 weeks

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function

Infant Multi-Breath washout Study

Lung Clearance Index (LCI) measured by multiple breath washout (MBW) has been shown to be a sensitive and non-invasive method of detecting early airways disease in infants with cystic fibrosis (CF). An abnormal measurement at a young age has been shown to track into later life, and could identify children that require more aggressive treatment earlier on. Currently however there is a lack of multi-centre data and of suitable scalable methodologies that can be used outside of highly specialised settings. This is a multi-centre longitudinal observational study of this measurement, LCI, in children younger than 3 years with CF, with a healthy control group and a disease group of babies who were born early. A novel method for MBW will be used, which has been developed and previously assessed in a pilot study at RMCH. We aim to show that LCI can be reliably measured across multiple centres using this method, with high rates of success and repeatability in the short term (2-3 months). We will also track any change in the children with CF and ex-premature babies in the longer term (12-18months). All parents will be consented prior to taking part in the study. The first LCI measurements on children with CF will be undertaken as soon as possible after diagnosis or recruitment, then 2-4 months and 12-18 months later. Infants who were born early (currently well, with no supplemental oxygen requirement) will have LCI close to, and ideally before NICU discharge and then 12 months later. Healthy controls under 3 years of age with no other comorbidity or respiratory concerns will be seen once whilst being sedated for other investigations. The children will be sedated as per local protocol, but at lower doses than previously used and than routinely used for scans in order to allow quicker discharge.

Read more Not Applicable
  • Trial Reference Number

    107844

  • Trial status

    Open to recruitment

  • Therapeutic category

    Other

26-30 of 56 results for all trials